

FOOD AND DRUG ADMINISTRATION (FDA)
Center for Drug Evaluation and Research (CDER)

Oncologic Drugs Advisory Committee (ODAC) Meeting
February 10, 2022

MEETING ROSTER

ACTING DESIGNATED FEDERAL OFFICER (Non-Voting)

LaToya Bonner, PharmD

Division of Advisory Committee and Consultant Management
Office of Executive Programs, CDER, FDA

ONCOLOGIC DRUGS ADVISORY COMMITTEE MEMBERS (Voting)

Ranjana H. Advani, MD

Physician Leader, the Lymphoma Clinical Care
Program
Saul A. Rosenberg Professor of Lymphoma
Stanford University Medical Center
Stanford, California

Mark R. Conaway, PhD

Professor and Director of Translational Research
Division of Translational Research and Applied
Statistics
Department of Public Health Sciences
University of Virginia
Charlottesville, Virginia

Massimo Cristofanilli, MD, FACP

Chief of Breast Medical Oncology
Associate Director of Precision Medicine
Meyer Cancer Center (MCC)
Scientific Director of the Englander Institute of
Precision Medicine (EIPM)
Weill Cornell Medicine
Division of Hematology-Oncology
New York, New York

Jorge A. Garcia, MD, FACP

Chair, Division of Solid Tumor Oncology
George and Edith Richman Distinguished Scientist
Chair
Director, GU Oncology Program
University Hospitals Seidman Cancer Center
Case Comprehensive Cancer Center
Case Western Reserve University
Cleveland, Ohio

Pamela L. Kunz, MD

(Acting Chairperson)
Associate Professor
Department of Medicine, Division of Oncology
Yale University School of Medicine
Director, Center for Gastrointestinal Cancers at
Smilow Cancer Hospital and Yale Cancer Center
New Haven, Connecticut

Christopher H. Lieu, MD

Associate Professor of Medicine
Associate Director for Clinical Research
Director, Gastrointestinal Medical Oncology Program
University of Colorado
Aurora, Colorado

Ravi A. Madan, MD

Clinical Director
Genitourinary Malignancies Branch
Center for Cancer Research
National Cancer Institute
National Institutes of Health
Bethesda, Maryland

David E. Mitchell

(Consumer Representative)
Founder, Patients for Affordable Drugs
Bethesda, Maryland

FOOD AND DRUG ADMINISTRATION (FDA)
Center for Drug Evaluation and Research (CDER)

Oncologic Drugs Advisory Committee (ODAC) Meeting
February 10, 2022

MEETING ROSTER (cont.)

ONCOLOGIC DRUGS ADVISORY COMMITTEE MEMBERS (Voting) cont.

Jorge J. Nieva, MD

Associate Professor of Clinical Medicine
Section Head, Solid Tumors
University of Southern California (USC) Norris
Comprehensive Cancer Center
Keck School of Medicine of USC
Los Angeles, California

Ashley Rosko, MD

Associate Professor
Division of Hematology
Department of Internal Medicine
Medical Director, Oncogeriatric Program
James Comprehensive Cancer Center
The Ohio State University
Columbus, Ohio

Anthony D. Sung, MD

Associate Professor of Medicine
Duke University School of Medicine
Duke Adult Blood and Marrow Transplant Clinic
Durham, North Carolina

ONCOLOGIC DRUGS ADVISORY COMMITTEE MEMBER (Non-Voting)

Jonathan D. Cheng, MD

(Industry Representative)
Senior Vice President
Head of Oncology Development
Global Drug Development
Bristol-Myers Squibb
Lawrenceville, New Jersey

TEMPORARY MEMBERS (Voting)

Karen E. Arscott, DO, MSc

(Patient Representative)
Jermyn, Pennsylvania

Ibiayi Dagogo-Jack, MD

Assistant Professor of Medicine
Harvard Medical School
Massachusetts General Hospital
Boston, Massachusetts

John Deeken, MD

President, Inova Schar Cancer Institute
Senior Vice President, Inova Health System
Professor of Medicine, University of Virginia
Fairfax, Virginia

Antoinette J. Wozniak, MD

Professor of Medicine
Division of Hematology/Oncology
Department of Medicine
University of Pittsburgh
Associate Director for Clinical Research
Leader, Lung Cancer Disease Center
UPMC Hillman Cancer Center
Pittsburgh, Pennsylvania

FOOD AND DRUG ADMINISTRATION (FDA)
Center for Drug Evaluation and Research (CDER)

Oncologic Drugs Advisory Committee (ODAC) Meeting
February 10, 2022

MEETING ROSTER (cont.)

FDA PARTICIPANTS (Non-Voting)

Richard Pazdur, MD

Director, Oncology Center of Excellence (OCE)
Director (Acting)
Office of Oncologic Diseases (OOD)
Office of New Drugs (OND), CDER, FDA

Julia Beaver, MD

Chief of Medical Oncology, OCE
Deputy Director (Acting), OOD
OND, CDER, FDA

Harpreet Singh, MD

Director
Division of Oncology 2 (DO2)
OOD, OND, CDER, FDA

Paz J. Vellanki, MD, PhD

Medical Officer
DO2, OOD, OND, CDER, FDA

Nicole Drezner, MD

Clinical Team Lead
DO2, OOD, OND, CDER, FDA